Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 162,704 shares, a decline of 96.7% from the September 30th total of 4,925,958 shares. Based on an average trading volume of 1,598,172 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.9% of the shares of the stock are short sold.
Wall Street Analyst Weigh In
SLXN has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.
Read Our Latest Stock Report on Silexion Therapeutics
Silexion Therapeutics Stock Down 7.6%
SLXN traded down $0.01 during trading on Monday, reaching $0.17. The company had a trading volume of 1,207,104 shares, compared to its average volume of 18,712,700. The business has a 50 day simple moving average of $0.31 and a 200-day simple moving average of $7.45. Silexion Therapeutics has a 52 week low of $0.14 and a 52 week high of $35.60.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last announced its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, beating the consensus estimate of ($21.20) by $16.03. On average, sell-side analysts expect that Silexion Therapeutics will post -4.70 EPS for the current year.
Silexion Therapeutics Company Profile
Silexion Therapeutics Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat.
Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment.
The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs.
Recommended Stories
- Five stocks we like better than Silexion Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
